Panitumumab

帕尼单抗

Report date: 2025/12/09 17:34:04

Base Information

Drug NamePanitumumab
Drug Alias NameAnti-EGFR monoclonal antibody潘尼单抗帕妥木单抗PanitumumabumrHuMAb-EGFr +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursExanthemaNeoplasm Metastasis +[24] 
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/09/27
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityAmgen Europe BvNational Cancer Institute Naples +[8] 
Inactive CompaniesRadboud University Medical CenterOngin Company LtdMansoura University +[11] 
Active IndicationsLung NeoplasmsBrain NeoplasmsPancreatic Neoplasms +[6] 
Inactive IndicationsSolid tumoursExanthemaNeoplasm Metastasis +[18] 

Other Information

ATC CodeL01XC08
Related LinksWikipediaDrugBankKEGG